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Abstract 
Background: To optimise care HIV patients need to be promptly initiated on antiretroviral therapy (ART) and subse-
quently retained on treatment. In this study we report on the interval between enrolment and treatment initiation, 
and investigate subsequent attrition and mortality of patients on ART at a rural clinic in Malawi.
Methods: HIV-positive individuals were recruited to a cohort study between January 2008 and August 2011 at 
Chilumba Rural Hospital (CRH). Outcomes were ascertained, up to 7 years after enrolment, through follow-up and 
by linkage to ART registers and the Karonga Health and Demographic Surveillance System (KHDSS). Kaplan–Meier 
methods and Cox regression were used to examine ART initiation after enrolment, mortality after ART initiation, and 
attrition after ART initiation.
Results: Of the 617 individuals recruited, 523 initiated ART between January 2008 and January 2015. Median time 
from HIV testing to commencement of ART was 59 days (IQR: 10–330). By a year after enrolment 74.2 % (95 % CI 
70.6–77.7 %) had initiated ART. Baseline clinical data at ART initiation and data on attrition was only available for the 
438 individuals who initiated ART during active follow-up, between January 2008 and August 2011. Of these individu-
als, 6 were missing Ministry of Health numbers, leaving 432 included in analyses of attrition and mortality. At 4 years 
after ART initiation 71.3 % (95 % CI 65.7–76.2 %) of these patients were retained on treatment at the CRH and 17.2 % 
(95 % CI 13.8–21.4 %) had died. Participants who had a lower CD4 count at enrolment (≤350 cells/μl), enrolled in 
2008, or tested for HIV at the CRH rather than through serosurveys, initiated treatment faster. Once on treatment, 
mortality rates were higher in patients who were HIV tested at the CRH, male, older (≥35 years), missing a CD4 count, 
or underweight (BMI < 18.5) at ART initiation.
Conclusions: Through linkage to the KHDSS and ART registers it was possible to continue follow-up beyond the end 
of the initial cohort study. Annual mortality after ART initiation remained considerable over a period of 4 years. Greater 
access to HIV and CD4 testing alongside initiation at higher CD4 counts, as planned in the test and treat strategy, 
could reduce this mortality.
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Background
Over the last decade access to antiretroviral therapy 
(ART) has increased substantially worldwide, particu-
larly in sub-Saharan Africa. In Malawi ART coverage 
has increased from an estimated 31,000–35,000 peo-
ple receiving ART in 2005 to 431,000 by 2013 [1–3]. To 
achieve this scale up of ART, Malawi adopted a public 
health approach with simplified treatment protocols and 
decentralised treatment [4, 5].
In January 2003 ART was available at the three larg-
est regional hospitals in Malawi only [2]. By September 
2005 the number of sites providing treatment in Malawi 
had increased to 60 [2]. In Karonga District, the site of 
this study, the number of sites to access ART increased 
from 1 in 2005 to 4 by 2008 [6]. Decentralisation contin-
ued during the follow-up period of this study and by 2012 
there were 16 ART clinics in the district [6]. Increasing 
peripheralisation of delivery has resulted in continued 
improvements in mortality [7, 8].
While more people are receiving ART, the number 
eligible has also increased due to changes to the CD4 
count threshold at which ART is initiated. In Malawi, in 
line with new recommendations from the World Health 
Organisation, the CD4 count threshold increased to 
350  cells/μL in 2011, and then to 500  cells/μL in April 
2014 [6, 9].
To maximise the impact of ART, people living with HIV 
should be diagnosed early, enrolled and retained in pre-
ART care, initiated on ART and retained in ART care. 
Engagement along the complete treatment cascade will 
determine the long-term success of the global response 
to HIV.
This study examines the outcomes of a cohort of indi-
viduals with HIV recruited at a rural ART clinic in 
Karonga District in Malawi. To be eligible for the study, 
individuals had to be resident in the Karonga Health 
and Demographic Surveillance Site (KHDSS). The study 
focuses on ART initiation after enrolment, mortality after 
ART initiation, and attrition after ART initiation.
Methods
The demography and the epidemiology of HIV in this pop-
ulation are well characterized [6, 8, 10–14]. Serosurveys 
were conducted within the KHDSS between 2006 and 2010 
[11]. In 2007/2008, at the time of initiation of the cohort 
study, crude HIV prevalence was estimated to be 6.8  % 
for adult men and 8.7 % for adult women [11]. Within the 
KHDSS it is estimated that by 2010 79  % of women and 
85 % of men had been tested for HIV at least once [11].
Data collection
From January 2008 to August 2011 HIV-positive adults 
attending the ART clinic at Chilumba Rural Hospital 
(CRH) for the first time were recruited to the cohort 
study. Those who met the inclusion criteria were regis-
tered in the study.
Inclusion criteria were having a documented positive 
HIV test, being older than 15 years, being resident in the 
KHDSS, and having given informed consent to partici-
pate in the study.
At enrolment patients were interviewed and catego-
rised by WHO stage. Blood was taken for CD4 count 
testing conducted at the research site laboratory. 
Between 2008 and 2011, in line with Malawi Ministry 
of Health Guidelines, HIV-positive individuals were 
eligible for ART if they were WHO stage III or IV, or 
had an absolute CD4 count below 250  cells/μL [15]. 
CD4 count criteria were adjusted upward to 350 cells/
μL in 2011.
Patients initiating ART were given individual and 
group counselling before being provided with antiretro-
viral medication. The primary drug regimen used was a 
fixed-dose combination of stavudine, lamivudine and 
nevirapine (Triomune® d4T-3TC-NVP).
Both patients who initiated ART and those not initially 
eligible were scheduled for clinical assessment every 
3 months. CD4 count testing was offered every 6 months. 
Those who became eligible for treatment on the basis of 
WHO stage or CD4 count were initiated on ART. Par-
ticipants were visited at home if they were more than a 
month late for a clinic appointment and had given con-
sent for such home visits at enrolment.
Active follow-up through the cohort study continued 
up until August 2011 at which point routine collection 
of clinical data ceased and patients entered usual care 
with less frequent appointments and reduced CD4 cell 
count monitoring. Thereafter outcome ascertainment 
was conducted by reviewing the CRH ART register in 
July 2013 for information on retention and mortality 
of participants who initiated ART during active-follow 
up, reviewing KHDSS data up to January 2015 for infor-
mation on mortality and ART initiation status, and 
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examining data from all ART registers in Karonga Dis-
trict up to August 2014 for information on ART initia-
tion status.
Patients who enrolled in the study but initiated treat-
ment outside of active follow-up (i.e. at another ART 
clinic in the district or after the initial cohort ended), 
were identified through the KHDSS and through ART 
registers of all clinics in Karonga District linked by 
identifiers collected from consenting individuals in a 
separate study [6]. All participants of the KHDSS self-
report on HIV and ART status, through an annual sur-
vey. The utility of HIV and ART status self-reporting 
has been demonstrated by a separate study in Karonga 
District [16].
All deaths of KHDSS participants are registered by a 
medical assistant who conducts a verbal autopsy [10]. 
An earlier evaluation found that 99 % of deaths were cap-
tured through the KHDSS over a 2 year period [17]. The 
ART clinic at which this study was conducted is the main 
government health facility within the boundaries of the 
KHDSS [10].
Data analysis
Kaplan–Meier methods and Cox regression were used to 
examine ART initiation after enrolment, attrition after 
ART initiation, and mortality after ART initiation.
All enrolled patients over 15  years old were included 
in survival analyses examining ART initiation after 
enrolment. Individuals who were not recorded to have 
initiated ART in the ART registers or the KHDSS were 
censored at the last date reported alive and not on ART. 
Univariable and multivariable Cox regression analyses 
were used to examine the effect of age at enrolment, sex, 
enrolment year, CD4 count at enrolment, and route of 
HIV testing, on ART initiation.
Only enrolled patients who initiated ART at the study 
clinic during active follow-up (January 2008 to August 
2011), and who had a Ministry of Health ID number 
(needed to identify patients on the CRH ART register), 
were included in the analyses of time from ART initiation 
to attrition or death. Individuals who initiated ART at 
other clinics or outside of active follow-up were excluded 
from these analyses due to a lack of clinical data on base-
line patient characteristics at ART initiation and data on 
attrition from the CRH ART register.
Attrition was defined as a one-time event of either loss 
to follow-up from the CRH ART clinic or death. For all 
patients the end date was their last clinic visit before July 
2013 when the CRH ART register was reviewed in depth. 
Those patients who had not been to an appointment at 
the CRH in the 4 months before 1st July 2013 were con-
sidered to be non-retained, either through loss to follow-
up or death. Clinic appointments were every 3  months 
and, in line with the study protocol, patients more than 
1 month late for an appointment were considered to have 
defaulted.
In the analysis of mortality participants who were not 
reported to have died in either the KHDSS or in the CRH 
ART register were censored on the most recent date 
known to be alive and resident in the KHDSS.
For Cox regression analyses of mortality, character-
istics at ART initiation were included if they had previ-
ously been identified to, or could plausibly, affect the 
outcome. The following baseline variables were included 
in survival analyses: sex, age, body mass index (BMI), 
CD4 count, WHO stage and year ART initiated. All vari-
ables included in univariable analysis were included in 
the multivariable Cox regression analysis with the excep-
tion of WHO stage, which was excluded as it is strongly 
correlated with CD4 count.
For all Cox regression analyses the significance of each 
factor was tested using likelihood ratio tests and the pro-
portional hazard assumption was assessed using Schoen-
feld residuals.
All statistical analyses were performed using Stata 12.0 
(Stata Corporation, College Station, TX, USA).
Ethics, consent and permissions
This research was approved by the National Health Sci-
ences Research Committee in Malawi (NHSRC#419 & 
#448) and the Ethics Committee of the London School of 
Hygiene and Tropical Medicine (LSHTM#5081 & #5214). 
Informed consent was obtained from all patients who 
took part in this study.
Results
Enrolment
Between January 2008 and August 2011, 617 patients 
with HIV were enrolled in the cohort study (Fig.  1 and 
Table  1). Participants were more likely to be female 
(59.8  %). The median age was 37  years and the median 
CD4 count was 239  cells/μL. The route of HIV testing 
was split with 44.6 % of participants having been tested at 
the CRH, 44.9 % at their home through a HIV serosurvey, 
Page 4 of 11Brown et al. AIDS Res Ther  (2016) 13:24 
and 10.5 % of participants missing information on route 
of HIV testing.
ART initiation
Between January 2008 and January 2015, 523 participants 
were recorded to have initiated ART. The majority of par-
ticipants initiated ART within 3  months of enrolment 
(65.7 %, 95 % CI 61.8–69.4 %). The proportion who had 
initiated ART increased to 74.2 % (95 % CI 70.6–77.7 %) 
by 1 year, 80.3 % (95 % CI 76.9–83.4 %) by 2 years, 84.2 % 
(95 % CI 81.1–87.1 %) by 3 years, 88.0 % (95 % CI 85.0–
90.6 %) by 4 years, and 90.8 % (95 % CI 87.9–93.3 %) by 
5 years after enrolment (Fig. 2). Among the 315 partici-
pants with a CD4 count at enrolment of less than or equal 
to 250  cells/μL, 294 (93.3  %) initiated ART promptly, 
within 3 months of enrolment.
Of the 94 individuals with no recorded ART initiation, 
91 had a CD4 count at enrolment. Median CD4 count 
among these 91 individuals was 507 cells/μL (IQR: 381–
676). Among the 94 individuals with no recorded ART 
initiation date there were 13 recorded deaths, 8 of which 
occurred in the first 200 days following enrolment.
Median time to initiate ART, among the 523 who 
started treatment, was 59  days from HIV testing (IQR: 
10–330) and 10  days from enrolment (IQR: 3–87). The 
median time to initiate ART after HIV testing was greater 
in those who started ART after being tested through a 
HIV serosurvey (189  days; IQR: 41–597) compared to 
those tested at the CRH (16 days; IQR: 6–94).
In both univariable and adjusted multivariable analysis 
of ART initiation there is strong evidence that CD4 count 
at enrolment, year of enrolment, and route of HIV test-
ing are associated with rate of ART initiation (Fig. 3 and 
Table 2). The ART initiation rate is higher in participants 
who had tested for HIV at the CRH, had a CD4 count 
less than or equal to 350 cells/μL at enrolment, and those 
who were enrolled in 2008. There is strong evidence for a 
higher rate of ART initiation in men in univariable analy-
sis. However, in adjusted analysis this effect disappeared.
Of the 523 individuals who initiated ART, only the 
432 who initiated ART during active follow-up and had 
a Ministry of Health ID number were included in analy-
ses of attrition and mortality (Fig. 1 and Table 3). The 85 
individuals who initiated ART outside of active-follow 
438 recorded to have 
started ART in inial cohort 
data 
619 individuals enrolled in 
cohort study 
617 included in further 
analysis 
2 excluded due to age 
below 15 
6  individuals with unknown 
Ministry of Health ID No. 
523 started ART by 31st
January 2015 
94 with no recorded ART 
start by 31st January 2015 
432 individuals included in  
analyses of arion and 
mortality 
85 only reported to start 
ART in KHDSS or ART 
register data  
Fig. 1 Flow diagram of participants
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up were excluded as they had no baseline clinical data at 
ART initiation or data on attrition. The 6 individuals with 
unknown Ministry of Health ID number were excluded as 
ID number was needed to link to data in the ART register.
At ART initiation patients were more likely to be 
WHO Stage III or IV (58 %). The median CD4 count was 
156  cells/μL. Patients who had tested for HIV through 
a serosurvey rather than at the CRH had higher CD4 
counts on average (Table 3).
Attrition on ART
Between January 2008 and July 2013, 101 of 432 indi-
viduals who started ART were lost to follow-up or died 
according to the CRH ART register. Of these 101 indi-
viduals 67 (15.5  % of those who initiated ART) were 
recorded as lost to follow-up and 34 (7.9 %) as dead. By 
cross-linking to the KHDSS it was possible to identify 
that 20 of the 67 individuals reported as lost to follow-up 
had died within 6 months of their last appointment.
At 3 months after ART initiation an estimated 92.1 % 
(95 % CI 89.1–94.3 %) of patients were retained on treat-
ment (Fig.  4). Retention decreases to 87.3  % (95  % CI 
83.7–90.1 %) by 1 year, 82.8 % (95 % CI 78.8–86.2 %) by 
2  years, 79.2  % (95  % CI 74.8–83.0  %) by 3  years, and 
71.3 % (95 % CI 65.7–76.2 %) by 4 years after initiation.
Mortality on ART
In an analysis of mortality using both KHDSS and 
CRH ART register data, 74 of 432 participants were 
recorded to have died between January 2008 and Janu-
ary 2015.
At 3 months after initiation an estimated 4.2 % (95 % CI 
2.7–6.6 %) had died. This increased to 8.0 % (95 % CI 5.8–
11.1 %) by 1 year, 12.2 % (95 % CI 9.4–15.7 %) by 2 years, 
14.0 % (95 % CI 11.0–17.8 %) by 3 years, 17.2 % (95 % CI 
13.8–21.4 %) by 4 years, and 18.1 % (95 % CI 14.5–22.4 %) 
by 5 years.
There was strong evidence that all of the variables 
included in the adjusted analysis, with the exception 
of year of ART initiation, were associated with mortal-
ity (Table 4). Lower BMI (<18.5), male sex, missing CD4 
count, and older age (≥35  years) were associated with 
increased mortality. Individuals who had been tested for 
HIV through the CRH had a higher mortality rate than 
those tested through a HIV serosurvey.
Discussion
Prompt initiation of ART, retention on treatment and the 
prevention of mortality are key components to successful 
HIV control and treatment. Through linkage to a demo-
graphic surveillance system and ART registers this study 
was able to ascertain ART initiation date and vital status of 
a cohort of people with HIV up to 7 years after enrolment.
Table 1 Patient characteristics at enrolment to the study
Total—n 617
Registered within KHDSS—n (%) 566 (92)
Route of HIV testing—n (%)
  CRH 275 (45)
  HIV serosurvey 277 (45)
  Missing 65 (11)
 Sex—n (%)
  Male 248 (40)
  Female 369 (60)
 Age—n (%)
  15–34 257 (42)
  ≥35 360 (58)
  Median age—years 37.0
 Weight—kg
  Median (IQR) 52.6 (47.8–59.0)
  Median BMI 20.2
 Year—n (%)
  2008 227 (37)
  2009 175 (28)
  2010 148 (24)
  2011 67 (11)
 WHO stage—n (%)
  I 122 (20)
  II 251 (41)
  III 196 (32)
  IV 48 (8)
 CD4 count—n (%)
  ≤250 cells/μL 315 (51)
  251–350 cells/μL 93 (15)
  351–500 cells/μL 85 (14)
  >500 cells/μL 109 (18)
  Missing 15 (2)
 Median CD4 count—cells/μL (IQR)
  Overall 239 (122–420)
 By sex
  Male 188 (89–345)
  Female 273 (152–466)
 By route of HIV testing
  CRH 187 (85–382)
  HIV serosurvey 277 (156–468)
  Missing 240 (127–404)
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The majority of patients initiated ART within 1 year of 
enrolment (74.2  %). Testing for HIV through the CRH 
rather than through a HIV serosurvey was associated 
with more rapid ART initiation, a higher CD4 count at 
initiation, and increased mortality. This finding high-
lights the importance of HIV testing uptake and access. 
Furthermore, it underlines the need to have both facility-
based testing to access the sickest patients as well as large 
scale community testing, with the different approaches 
accessing different HIV populations.
This study has a number of advantages includ-
ing extended follow-up, accurate death data from the 
KHDSS, and linkage to district wide ART registers. ART 
delivery at the CRH used government designed and ini-
tiated protocols. Where a difference existed it was the 
presence of Karonga Prevention Study (KPS) clinical staff 
and proximity to the KPS laboratory where CD4 count 
testing was undertaken. The link to the research site may 
have impacted the perceived quality of and access to care 
and the speed of CD4 count testing. Thus the site func-
tioned more like a bigger hospital clinic setting than a 
rural health centre.
ART initiation
As would be expected CD4 count was strongly associated 
with more rapid initiation of ART with an unadjusted 
hazard ratio of 0.12 (95 % CI 0.09–0.16) in patients with a 
CD4 count above 500 cells/μL at enrolment compared to 
below 250 cells/μL.
Enrolment decreased annually throughout the study as 
a result of the continuing decentralisation of ART pro-
vision. Individuals who enrolled in 2008 initiated ART 
more rapidly than those who enrolled in subsequent 
years. We would suggest that this is a consequence of 
establishing the research team within the clinic and pro-
viding CD4 count testing that encouraged a backlog of 
Table 2 Factors affecting time to initiate ART
Factor Unadjusted analysis Adjusted analysis
Hazard ratio 95 % CI p-value Hazard ratio 95 % CI p-value
Sex 0.012 0.930
Male 1 (ref ) 1 (ref )
Female 0.80 0.67–0.95 0.99 0.83–1.19
Age at enrolment 0.259 0.996
15–34 1 (ref ) 1 (ref )
≥35 1.11 0.93–1.32 1.00 0.83–1.20
CD4 count (cells/μL) at enrolment <0.001 <0.001
≤250 1 (ref ) 1 (ref )
251–350 0.36 0.28–0.47 0.35 0.27–0.46
351–500 0.18 0.13–0.25 0.17 0.13–0.24
>500 0.12 0.09–0.16 0.12 0.09–0.17
Missing 0.71 0.40–1.27 0.74 0.41–1.33
Year of enrolment 0.002 <0.001
2008 1 (ref ) 1 (ref )
2009 0.69 0.56–0.86 0.62 0.49–0.77
2010 0.89 0.71–1.11 0.74 0.59–0.93
2011 0.66 0.48–0.91 0.60 0.44–0.83
Route of HIV testing <0.001 0.009
CRH 1 (ref ) 1 (ref )
HIV serosurvey 0.71 0.59–0.85 0.75 0.62–0.91
Missing 1.04 0.77–1.41 1.01 0.74–1.38
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individuals who were otherwise well and had failed to 
attend or initiate ART earlier.
Women initiated ART at a significantly slower rate 
than men in an unadjusted analysis, which corresponds 
with findings from other studies [18, 19]. However, after 
adjusting for CD4 count this effect disappeared. Men on 
average presented with lower CD4 counts than women, 
which may explain this effect [20]. Suggested causes for 
men presenting with lower CD4 counts include stigma 
and social factors [21]. Another possible explanation is 
that CD4 counts may drop faster in men than women 
[22].
Patients tested for HIV at home as part of a HIV sero-
survey initiated ART less rapidly than those tested at the 
CRH. People who present to a clinic with undiagnosed 
HIV often do so due to illness [23, 24]. HIV serosurveys 
can identify individuals with clinically unapparent HIV 
infection who would not otherwise present to a clinic. 
Despite the longer time to start treatment, patients tested 
for HIV through a serosurvey still initiated ART with on 
average higher CD4 counts and had reduced mortality.
As highlighted by these findings, HIV testing is the 
essential first step in HIV care. To increase uptake the 
WHO recommends community-based HIV testing ser-
vices, provider initiated testing and counselling, and 
provision of testing services by lay workers using rapid 
diagnostic tests [25]. It is estimated that in 2013 45  % 
of people (aged 15–49) living with HIV in sub-Saharan 
Africa knew their HIV serostatus [1]. Uptake of HIV 
testing will have to increase substantially to meet the 
UNAIDS target of 90 % of people living with HIV know-
ing their serostatus by 2020 [26]. A promising strategy to 
further increase uptake, which is currently being evalu-
ated, is HIV self-testing [27].
Retention on ART
For those patients who initiated ART, retention on treat-
ment was high. A systematic review of sub-Saharan ART 
programmes between 2007 and 2009 found that the aver-
age retention at 1  year was 80.2 and 72.3  % at 3  years. 
[28]. The figures for this study are even more favourable 
with retention of 87.3 % at 1 year and 79.2 % at 3 years.
The retention rate reported is likely to be an underes-
timate of true retention in treatment as some individuals 
lost to follow up will have transferred to an ART clinic 
Table 3 Characteristics of  patients included in  analyses 
of attrition and mortality at initiation of ART
Total—n 432
Registered within KHDSS—n (%) 398 (92)
Route of HIV testing—n (%)
CRH 203 (47)
HIV serosurvey 181 (42)
Missing 48 (11)
Sex—n (%)
Male 189 (44)
Female 243 (56)
Age—n (%)
15–34 162 (38)
≥35 270 (63)
Median age—years 38.0
Weight—kg
Median (IQR) 52.9 (46.8–58.4)
Missing—n (%) 12 (3)
Median BMI 20.1
Year of ART initiation—n (%)
2008 150 (35)
2009 106 (25)
2010 117 (27)
2011 59 (14)
WHO stage—n (%)
1 49 (11)
2 134 (31)
3 203 (47)
4 46 (11)
CD4 count—n (%) cells/μL
≤250 285 (66)
251–350 33 (8)
351–500 14 (3)
>500 9 (2)
Missing 91 (21)
Median CD4 count—cells/μL (IQR)
Overall 156 (77–227)
By route of HIV testing
CRH 139 (62–222)
HIV serosurvey 167 (108–227)
Missing 169 (69–244)
Starting Regimen—n (%)
d4T-3TC-NVPa 431 (99.8)
TDF-3TC-EFVb 1 (0.2)
Clinical Details—n (%)
Weight loss >10 % 107 (25)
Oral candidiasis 74 (17)
Severe bacterial infection 72 (17)
Unexplained fever >1 month 32 (7)
Wasting syndrome 14 (3)
Pulmonary tuberculosis 12 (3)
Kaposi’s sarcoma 10 (2)
a Stavudine, lamivudine and nevirapine
b Tenofovir disoproxil fumarate, lamivudine and efavirenz
Table 3 continued
Total—n 432
Oesophageal candidiasis 9 (2)
Extrapulmonary tuberculosis 5 (1)
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other than the CRH, an outcome that is difficult to track 
with current health informatics systems in Malawi. This 
is one reason for the lower retention rates in this study 
than reported in a different study looking at all ART clin-
ics in Karonga District in 2011/2012 [6].
Mortality on ART
The mortality rate reported in this cohort is substantially 
higher than a pooled estimate from European studies, but 
comparable to other studies in sub-Saharan Africa that 
similarly account for unreported deaths amongst patients 
lost to follow up [29, 30]. The association between male sex, 
older age, low BMI and low CD4 count with increased mor-
tality replicate findings from other studies [20, 29, 31–33].
Men initiated ART at an older age and with more 
advanced disease. After adjusting for age and CD4 count, 
sex remained strongly associated with mortality. Higher 
mortality in male ART patients has been linked to lower 
retention on treatment and lower immune reconstitution 
[20, 34]. Residual confounding by CD4 count is an addi-
tional explanation for the remaining association.
With the increase in the CD4 count threshold for 
ART initiation to 500 cells/μL in 2014 the proportion of 
patients initiating ART early is likely to increase. Earlier 
initiation of treatment has been linked to prevention of 
transmission and improved clinical outcomes [35–38]. 
However, for the positive effect of early ART initiation on 
patient outcomes and HIV transmission to be realized, 
greater HIV testing coverage is needed alongside more 
CD4 count testing. As of 2012 only 11  % of facilities in 
Malawi with HIV services had the capability to perform 
CD4 testing [39].
Conclusions
Through linkage to a demographic surveillance system 
and ART registers we were able to extend follow-up 
beyond the initial cohort study and obtain more accu-
rate outcome data. Patients who had tested for HIV 
through a serosurvey rather than at the CRH clinic 
initiated ART with on average higher CD4 counts and 
subsequently had reduced mortality. More broadly, 
for patients on ART annual mortality over a period of 
0
.25
.5
.75
1
P
ro
po
rt
io
n 
re
ta
in
ed
 o
n 
A
R
T
0 1 2 3 4 5 6
Time from ART initation (years)
432 349 295 200 108 31 0
Number at risk
95% CI Proportion retained on ART
Fig. 4 Proportion retained on ART after treatment initiation
Page 10 of 11Brown et al. AIDS Res Ther  (2016) 13:24 
4 years after ART initiation was considerable. Increased 
coverage of HIV and CD4 testing combined with earlier 
initiation of ART, as now recommended, could reduce 
this mortality.
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